Pricing Log in Create free account

Clene Inc. (CLNN) vs Kalaris Therapeutics Inc. (KLRS)

Clene Inc. and Kalaris Therapeutics Inc. are both Biotechnology companies. Clene Inc. and Kalaris Therapeutics Inc. are of similar size ($47.8M and $47.0M). Kalaris Therapeutics Inc. has the higher net margin (0.00% vs −20,059.9%) and the higher return on invested capital (0.00% vs 0.00%). Across the 12 metrics below, Kalaris Therapeutics Inc. leads on 7 and Clene Inc. on 5.

Valuation

Metric CLNN KLRS Biotechnology median
P/E n/m n/m 8.50
P/S 194.86 n/m 9.71
P/B n/m 0.83 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m 0.55 0.64
EV/Sales 238.72 n/m 9.21
Earnings yield (112.90%) (101.00%) (33.15%)
Free cash flow yield (41.54%) (85.89%) (25.50%)

Profitability

Metric CLNN KLRS Biotechnology median
Gross margin 70.05% 0.00% 65.16%
Operating margin (10,431.98%) 0.00% 0.00%
Net margin (20,059.90%) 0.00% 0.00%
Free cash flow margin (8,095.43%) 0.00% 0.00%
Return on equity 237.15% (79.91%) (56.36%)
Return on assets (174.99%) (46.02%) (48.04%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric CLNN KLRS Biotechnology median
Revenue growth (TTM) (31.12%) — 6.02%
EPS growth (last fiscal year) 53.26% 94.50% 30.26%
Revenue growth, 5-year CAGR (0.59%) — 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric CLNN KLRS Biotechnology median
Debt to equity (0.74) 0.00 0.00
Current ratio 3.07 10.98 4.72
Net debt to EBITDA (0.39) 2.54 0.96

Dividend

Metric CLNN KLRS Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric CLNN KLRS Biotechnology median
Market cap 46.98m 47.83m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack